ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SUMM Summit Therapeutics Plc

20.50
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Summit Therapeutics Plc LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 20.50 18.00 23.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Summit Therapeutics Share Discussion Threads

Showing 38326 to 38348 of 41850 messages
Chat Pages: Latest  1542  1541  1540  1539  1538  1537  1536  1535  1534  1533  1532  1531  Older
DateSubjectAuthorDiscuss
01/4/2017
16:46
Happy birthday Dame Kay Davies
freedosh
30/3/2017
11:41
Agreed, HM, nothing negative reported and all looking good for long term value and a very healthy return on the current entry price. It's just a matter of when.
Many of us were hoping that 'when' was this Summer but I guess a further six months to wait for a more secure 'when' is better.

Q1 2018 is a tighter window for the results too, which should easily be met. Glyn did say yesterday that boys had already started on the F6 formulation. So the first half of the trial (20 boys doing the 24 week biopsy) should be done before too long. Great that they can continue on the treatment too.

Not selling a single share and all looking positive from my very long term holder point of view.
Remember it's only money to us, the main point is eventual success for the DMD community IMHO. GLA

freemoney1
30/3/2017
10:16
euroto ... good to see the NASDAQ pushing our shares up. Talking of 'misleading investors' the AIM MMs must think it's Christmas with insecure UK shareholders seeing yesterdays RNS as negative when the american market clearly see things gong from strength to strength.

I hope that any longtermers (Chris?) having sold shares yesterday, realise that the NASDAQ seems to be continuing to push things upward. Perhaps a few AIM sells won't hold things down for long, as those who have recently discovered Summit on AIM may see this as an opportunity to jump onboard before Q2 when C Diff results with FID v RDZ perhaps moves things up?

The american pundits all see yesterday's RNS and web discussion in nothing but positive light.

Cash looking good ... average forecasts suggesting value of $28 plus and "Buy".

hugus maximus
30/3/2017
09:41
HM this seems to be more about apparently misleading investors rather than an FDA matter. Could do with more of this in the UK IMHO.
euroto
30/3/2017
09:11
Just seen this announcement on Google Finance made on Monday (28th) about Saraepta investigation :



Not sure quite how relevant this is in light of FDA decision eventually pushing through the pain barrier with this? Not new "news". Any thoughts?

hugus maximus
29/3/2017
22:52
"Summit Therapeutics is cashed-up and looking forward to exciting year" (fom proactive investors)

"14:20 29 Mar 2017
The company is well-placed as it looks forward to the continuation of its Phase 2 proof of concept trial for its lead utrophin modulator, ezutromid, and preparation work on its ridinilazole antibiotic
Drugs developer Summit Therapeutics PLC (NASDAQ:SMMT, LON:SUMM) was sitting on a tidy cash pile of £28.1mln at the end of its financial year.

The cash leaves the rare diseases specialist well-placed to make further progress, as it looks forward to the continuation of its Phase 2 proof of concept trial for its lead utrophin modulator, ezutromid, and preparation work on its ridinilazole antibiotic, which the company hopes will be ready to enter Phase 3 clinical trials in the first half of 2018.

The licensing deal signed with Sarepta Therapeutics (NASDAQ:SRPT) was a highlight of last year, the company said as it issued results for the year to the end of January 2017.

The two companies will collaborate on Summit’s potentially breakthrough treatment for Duchenne Muscular Dystrophy (DMD).

As part of the deal, Sarepta paid Summit £32.8mln in advance, £2.3mln has been recognised as revenue for the year just ended.

That formed the bulk of the £2.9mln of revenue Summit reported for the year, up from £2.3mln the year before.

Research and development costs of £23.6mln, up from £19.0mln the previous year, and admin costs of £10.4mln (2015/6: £8.3mln) meant the drug discoverer posted a pre-tax loss of £32.4mln, compared to a loss the year before of £25.7mln.

With its flagship drugs still in development, however, the results statement was not really about the numbers; it was about the progress it made with its DMD and C. difficile (CDI) treatments.

"Our Phase 2 proof of concept trial, PhaseOut DMD, is well underway with enrolment expected to be completed in the second quarter of 2017. We now look forward to providing the full analysis of 24-week biopsies from the approximately 20 patients dosed with the F3 or F6 formulation of ezutromid, plus 24-week MRI and functional measures from all patients in the trial, in the first quarter of 2018,” said Glyn Edwards, chief executive officer of Summit.

“This approach is in lieu of reporting interim analysis from a smaller group in 2017, and it is expected to provide a more complete picture of the potential benefits of ezutromid at this time point on utrophin expression, muscle health and muscle function,” he added.

Read Summit rises as it presses on with extension of PhaseOut DMD trial

[...]

“In CDI, our Phase 2 clinical data supports the potential front-line use of ridinilazole to treat the initial infection and provide patients with a sustained clinical response. This sustained clinical response is the focus of our planned Phase 3 programme that is designed, with input from the FDA and EMA, to evaluate superiority of ridinilazole over the current standard of care antibiotic vancomycin,” Edwards said.

“With the Phase 3 trials planned to start in the first half of 2018, we look forward to an exciting and important time ahead as we seek to bring these two potentially important treatment options one step closer to patients," he concluded.

Shares in Summit are up 45% year-to-date but fell 0.7%, pretty much in line with the wider market, to 206p on the results."

------------
ps sorry for posting whole article but link would not post.

algernon2
29/3/2017
21:46
Hi Hugus,Totally agree with you about engaging in spin-along mode to await F6 results. Weak/conditional results from F3 alone could have got us into a tail-spin. (It also provides a time window to better establish the value of the C.Diff programme).I hadn't connected with the earlier RNS on extending the trials but if it is connected it would make a lot of sense.Overall a good day! Cheers, tightfist
tightfist
29/3/2017
21:12
Hi HM & freedosh I agree with you both & have always been sceptical about F3 when F6 was always the better option.We are now in a position to have to wait to next year so no cliff this year if results were not as hoped for.

The company is increasing staff levels to gear up the company for the next level which matches the news today.

If the share price holds Thursday supported by this evenings improved NASDAQ close (£2.14)I will be pleased & I now better understand the earlier DMD RNS this week.

chrisatrdg
29/3/2017
21:07
Summit Therapeutics PLC (ADR)
NASDAQ: SMMT - Mar 29, 4:00 PM EDT
13.28USDPrice increase0.67 (5.31%)



must be a blue day tomorrow

football
29/3/2017
17:50
Totally agree with your take, Hugus. I pressed for F6 from announcement of better absorption. If the EU deal was Sarepta's insurance, then this is surely ours.
freedosh
29/3/2017
14:13
Hi chris,If you are re-listening to the call can you please take note in the Q&A session about F3 and F6 being reported simultaneously. For me Glynn was less fluent in responding and (whilst some good rationale was presented) it made me wonder if they really do want to package it up and avoid any potential glitches if they went alone earlier with only F3.Also in the Q&A is the interesting aspect of partnering/funding to take RDZ through Phase 3. To my ears Glynn just stopped short of an unequivocal "no equity funding" commitment.Cheers, tightfist
tightfist
29/3/2017
13:12
Hi tightist - I agree with your comments & my reading of the situation prior to the conference call is that the RNS would be perceived as a 'delay' & would effect the share price I then decided at 12.59 to Sell 2,080 shares (re-investment of last Octobers profit)as I saw the share price was likely to drop but I was able to make a small return but no loss.

I hope that the next DMD payment will trigger a share price recovery.

The important thing is that the final DMD deadline has not been extended but it means that they are really going for the newer DMD drugs.

Edit: As I type the NASDAQ is up £ equivalent £2.16 so maybe wrong to Sell.

chrisatrdg
29/3/2017
12:38
Yes, Chris, it looks as though we may now need to seal a non-dilutive C.Diff deal to move the share price forward in the shorter term; sometimes I get the impression that SUMM are now in less of a hurry having received the Sarepta cash though partnership discussions are ongoing.Reassuringly I have heard on the conf. call that, assuming they safely receive the $22m Sarepta milestone payment, they will have sufficient cash through to 31/12/2018.Also the point has just been registered that the delay to Q1 2018 will enable F3 and F6 results to be analysed and reported simultaneously. This sounds to be potentially significant?
tightfist
29/3/2017
11:48
I am hoping that the effective delay in real DMD data to next year,as I read it,will not have an adverse effect on the share price as once again the timetable has effectively been pushed back again.We now need C-Diff to boost the share price Is my interpretation right ? Also need to get my head round the deferred income position - thats for latter.Regards.
chrisatrdg
29/3/2017
11:18
Yes, the Seeking Alpha person was spot-on. The upside potential of EZD and down-side protection of RDZ is powerful IMHO. Most likely there will be bumps along the way.....
tightfist
29/3/2017
10:43
Great info on Port Erin and there 2016 selling spree.... that explains why I was able to scoop up cheap shares last year thank you very much.
It seems we have a good stable +£2 share price now and if the Seeking Alpha chap is right we should run up to £3 before the results.
All irrelevant in the long run though.... +ve Ezutromid results will revalue the company by some margin. GLA

freemoney1
29/3/2017
08:31
Hi Waterloo,O/T: PEBI still hold around £700k in RPG. They also sold-down 20% of their Magna last year to free-up cash.We have not heard any more since last October on the reversing of DBC (see pulse-flow.net) into LIFE. Some news must be imminent as the LIFE and PEBI £200k loans time-out this Friday.Cheers, tightfist
tightfist
29/3/2017
08:11
tightfist, cheers. How many shares does Regent hold? Remember diabetic boot company from an event about 3-4 years ago. Wasn't wildly impressed (although mellon was/is) and note they have made very little real progress in the intervening years, but really don't follow so just a view.
waterloo01
29/3/2017
08:05
Hi Waterloo,Re: PEBI, they progressively sold-down their SUMM holding every quarter in 2016, and by year-end had sold 60% and retained just 120k shares. In contrast, Regent Pacific (traded in HK) has been left untouched.Why? My guess is that if investors want exposure to SUMM they just buy the AIM shares. Mellon seeks exposure to early-stage companies (such as those listed in this morning's report), so they are liquidating SUMM to free-up some cash, such as the loan to DBC which should progress this week?If the investors were equally keen PEBI would not be generally trading at 45-50% discount......Cheers, tightfist
tightfist
29/3/2017
07:19
Form 6-K Summit Therapeutics plc For: Mar 28






Q4 2016 Summit Therapeutics Plc Earnings Conference call
Starting in 4 hrs 50 mins





OPPENHEIMER HOLDINGS WEIGHS IN ON SUMMIT THERAPEUTICS PLC’S FY2021 EARNINGS.
MARCH 29, 2017

football
29/3/2017
06:42
Note Port erin results today and no mention of holding in Summit. Guess Mellon sold. Not sure when they did this.
waterloo01
28/3/2017
21:05
Your wish was (EDIT - almost) granted luminoso! Whatever ... a neat close in Nasdaqland. (Up a bit like this everyday is OK.)
hugus maximus
28/3/2017
17:30
Background/Key Assets:

Lead candidate ezutromid, an utrophin modulator, is being developed as a potential disease-modifying treatment for all DMD patients, not small subsets like many of its competitors. As utrophin shares many structural similarities to dystrophin, management believes it is functionally equal to the latter in terms of developing (and not losing) muscle.

Management at Sarepta Therapeutics saw the promise here, purchasing European rights to the treatment for $40 million upfront and up to $522 million in milestone and royalty payments. They were also granted an option for the Latin American market.

Novel antibiotic candidate ridinilazole has shown statistical superiority was shown over vancomycin in a prior phase 2 trial.

Upcoming Catalysts:

24 week biopsy data from an ongoing phase 2 proof of concept trial, dubbed PhaseOut DMD, involving 100 healthy volunteers and 22 DMD patients is due in the second or third quarter this year. If data is positive, the company plans to start a placebo-controlled phase 2 trial in the second half of the year, one which could support accelerated and conditional approval filings in 2019.

An exploratory phase 2 trial testing ridinilazole against fidaxomicin should see topline data reported in the second quarter.

Thesis and Risks:

I believe shares could run up significantly (50% or higher) before the data release- investors who have done their due diligence could buy shares in the near term. After a significant runup, I suggest taking partial or full profits to manage risk. Disappointing data from the ridinilazole trial would result in a share price drop, although a floor would be established due to the company's cash position and promising DMD asset. However, disappointing data from the PhaseOut DMD trial would be a significant blow to the company's future with much higher downside potential.

waterloo01
Chat Pages: Latest  1542  1541  1540  1539  1538  1537  1536  1535  1534  1533  1532  1531  Older

Your Recent History

Delayed Upgrade Clock